ArjoHuntleigh lured a former Covidien executive as its new president of North American operations.
Illinois healthcare products maker ArjoHuntleigh hired Rick Lytle, a former Covidien (NYSE:COV) executive, as the new president of company operations in the U.S. and Canada.
Covidien begins enrollment in a pair of clinical studies evaluating its Stellarex drug-coated angioplasty balloon in the U.S. and abroad.
Covidien (NYSE:COV) kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon.
S2N Health blogger Erin Warner travels to Africa for a look at the healthcare system. How can emerging medical device companies take advantage of this opportunity
By Erin Warner
The large medtech companies talk endlessly about emerging markets delivering their top-line growth targets, and they are not just talking about BRIC countries anymore.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Covidien could wind up with a nearly $450 million tax tab from its days as Tyco Healthcare, after the IRS nixes some $914 million in interest deductions dating back to the years 1997 through 2000.
Massachusetts-based Covidien officially becomes a pure-play medical device company after executing the spinout of its pharmaceuticals business into independently operated Mallinckrodt plc, which today began trading on the New York Stock Exchange.